{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:24:21Z","timestamp":1771889061273,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T00:00:00Z","timestamp":1389744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Epidermal growth factor receptor inhibitors (EGFRi) and MEK inhibitors (MEKi) are notorious for causing papulopustular rash. Treatment recommendations from studies and expert panels include, amongst others, oral tetracyclines. The efficacy of retarded low\u2010dose doxycycline (rld\u2010doxycycline), however, has not been investigated. The objective was to review the response and development of EGFRi\u2010 and MEKi\u2010induced rash under therapy with rld\u2010doxycycline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and method<\/jats:title><jats:p>A retrospective review of all patients treated with rld\u2010doxycyline 40\u00a0mg once daily between September 2011 and June 2012 for papulopustular rash. Rash development and severity (according to the Common Terminology Criteria of Adverse Events V4.0) were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen patients (13 men, 4 women) were treated with rld\u2010doxycycline while receiving EGFRi [monoclonal antibodies (mab) <jats:italic>n<\/jats:italic>\u00a0=\u00a08, tyrosine kinase inhibitors (TKi) <jats:italic>n<\/jats:italic>\u00a0=\u00a07] or MEKi (<jats:italic>n<\/jats:italic>\u00a0=\u00a02). In 47% (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>8) the rash was reduced by at least one grade, in 29% (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>5) the rash was stabilized, 24% (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>4) did not profit from the treatment. All patients treated with an EGFR\u2010TKi or a MEKi profited of the rld\u2010doxycycline. All patients who experienced deterioration were on treatment with an EGFR\u2010mab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rld\u2010doxycyline can improve EGFR\u2010TKi\u2010 and MEKi\u2010induced rash severity. Its effectiveness appears to be inferior to doxycycline 200\u00a0mg\/day in more severe cases and in EGFR\u2010mab\u2010induced rash, but due to the advantageous side\u2010effect profile, rld\u2010doxycycline should be considered as a possible treatment option for papulopustular rash. Prospective, randomized trials are necessary to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12365","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T07:50:48Z","timestamp":1389772248000},"page":"1685-1689","source":"Crossref","is-referenced-by-count":16,"title":["Retarded low\u2010dose doxycycline for EGFR or MEK inhibitor\u2013induced papulopustular rash"],"prefix":"10.1111","volume":"28","author":[{"given":"J.","family":"Vaubel","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,15]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1066"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"e_1_2_5_5_1","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors","volume":"4","author":"Lacouture ME","year":"2006","journal-title":"J Support Oncol"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.062"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.09.013"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04791.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4790"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000112795"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.09.005"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.s.009"},{"key":"e_1_2_5_13_1","first-page":"186","article-title":"Toward evidence\u2010based management of the dermatologic effects of EGFR inhibitors","volume":"23","author":"LoRusso P","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0114-0"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0131"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2005.05058.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23621"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0988-5"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.v16i1.361"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05082.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03167.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.1.1025697"},{"key":"e_1_2_5_24_1","first-page":"1","article-title":"Systemic therapy for rosacea","volume":"12","author":"Baldwin HE","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_5_25_1","first-page":"338","article-title":"Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer","volume":"10","author":"Li J","year":"2009","journal-title":"JOP"},{"key":"e_1_2_5_26_1","first-page":"274","article-title":"Malassezia folliculitis presented as acneiform eruption alter cetuximab administration","volume":"8","author":"Cholongitas E","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2008.n.010"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12365","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12365","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:45:05Z","timestamp":1695570305000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,15]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/jdv.12365"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12365","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,15]]}}}